

JUL 27 2005 K051516/S1

1.12

Summary of Safety and Effectiveness

Submitter: Zimmer, Inc.
P.O. Box 708
Warsaw, IN 46581-0708

Contact Person: Karen Cain
Manager, Corporate Regulatory Affairs
Telephone: (574) 372-4219
Fax: (574) 372-4605

Date: June 7, 2005

Trade Name: *Trabecular Metal*[™] Revision Shell Liners

Common Name: Acetabular Cup

Classification Name
and Reference: Prosthesis, Hip, Semi-Constrained, Metal/Polymer,
Cemented
21 CFR § 888.3350

Predicate Device: Implex Hydrocel[®] Replacement Cup Insert,
manufactured by Zimmer TMT (formerly known as
Implex), K983128, cleared December 3, 1998.

Device Description: This modified device is intended for cemented use
in conjunction with a *Trabecular Metal* Revision
Shell. The liner is offered in a broad range of sizes
with 0- and 10-degree face angle versions to
accommodate a variety of patient anatomies.

Intended Use: The *Trabecular Metal* Revision Shell Liners are
indicated for cemented use in the *Trabecular Metal*
Revision Shell for initial placement or as an in situ
replacement polyethylene bearing surface for joint
instability, wear and/or damage.

Comparison to Predicate Device: Except for a change in material and minor
dimensional changes, the *Trabecular Metal*
Revision Shell Liners are identical to the predicate
device. The modified device uses the same
operating principle, intended uses and fixation
method as the predicate device.

20/2

**Performance Data (Nonclinical
and/or Clinical):****Non-Clinical Performance and Conclusions:**

Non-clinical testing demonstrated that the
Trabecular Metal Revision Shell Liners are
substantially equivalent to the predicate device.

Clinical Performance and Conclusions:

Clinical data and conclusions were not needed for
this device.



JUL 27 2005

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Ms. Karen Cain
Manager, Corporate Regulatory Affairs
Zimmer, Inc.
P.O. Box 708
Warsaw, Indiana 46581-0708

Re: K051516

Trade/Device Name: Trabecular Metal™ Revision Shell Liners
Regulation Number: 21 CFR 888.3350
Regulation Name: Hip joint metal/polymer semi-constrained cemented prosthesis
Regulatory Class: II
Product Code: JDI
Dated: July 14, 2005
Received: July 15, 2005

Dear Ms. Cain:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,

A handwritten signature in black ink, appearing to read "Mark N. Melkerson", is written over the typed name.

Mark N. Melkerson
Acting Director
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

K 051516/51

- 121

Indications for Use

510(k) Number (if known):

Device Name:

Trabecular Metal™ Revision Shell Liners

Indications for Use:

The *Trabecular Metal* Revision Shell Liner is indicated for cemented use in the *Trabecular Metal* Revision Shell for initial placement or as an in situ replacement polyethylene bearing surface for joint instability, wear and/or damage.


Prescription Use X
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use _____
(21 CFR 807 Subpart C)

(Please do not write below this line – Continue on another page if needed)

Concurrence of CDRH, Office of Device Evaluation (ODE)


(Division Sign-Off)
Division of General, Restorative,
and Neurological Devices

Page 1 of 1

510(k) Number K051516